Niagen Bioscience
Health & Nutrition Products · 51-200 Employees
View Company Info for Free
Overview
Website
www.niagenbioscience.comRevenue
$99.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Niagen Bioscience
Niagen Bioscience Inc is a publicly traded bioscience company headquartered in Los Angeles, California, trading on NASDAQ under the ticker symbol NAGE. Founded in 1999 as ChromaDex Corporation, the company officially changed its name to Niagen Bioscience in March 2025, reflecting its focus as the global leader in nicotinamide adenine dinucleotide NAD+ research and technology. The company operates through three business segments including consumer products, ingredients, and analytical reference standards and services. Niagen Bioscience specializes in developing, manufacturing, and commercializing proprietary ingredient technologies centered around Niagen, its patented nicotinamide riboside chloride, which serves as an NAD+ precursor clinically proven to increase NAD+ levels by up to 150 percent. The company's product portfolio includes Tru Niagen, a premium food-grade oral supplement for daily cellular vitality sold directly to consumers through its proprietary e-commerce platform, AmazRead more
Popular SearchesNiagen Bioscience IncSIC Code 28,283NAICS Code 32,325Show moreNiagen Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Niagen Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Niagen Bioscience has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Niagen Bioscience had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Niagen Bioscience has new funding data
Niagen Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Niagen Bioscience launches new products
Earning: See what the market has to say on Niagen Bioscience recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Niagen Bioscience
Check out if Niagen Bioscience is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Niagen Bioscience as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Niagen Bioscience is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Niagen Bioscience is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Niagen Bioscience.
Niagen Bioscience Tech Stack
Most Recent Scoops
Earnings
reported general and administrative expense of $7.5 million, an increase of $6.4 million versus last year, primarily driven by the absence of a $3.5 million reversal of previously accrued royalties and license maintenance fees, along with higher share-based compensation expense.
Earnings, Accounting, Financial Reporting, Finance
Earnings
reported net income of $17.4 million for the year compared to $8.6 million in fiscal year 2024.
Earnings, Finance
Earnings
reported selling and marketing expense was 30.8% of sales in Q4, compared to 29.9% in Q4 2024.
Sales
Earnings
reported that general and administrative expense was up $8.7 million year-over-year, primarily driven by an increase in employee-related expense and stock-based compensation of $3.8 million, increase in consulting fees of $1.5 million, and higher royalty expense of $2.9 million due to the absence of a $3.5 million reversal of previously accrued royalties and license maintenance fees which occurred in the prior year.
Earnings, Accounting, Financial Reporting, Finance
Earnings
Earnings, Finance, Financial Operations
Niagen Bioscience News & Media
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call March 4, 2026 4:30 PM ESTCompany ParticipantsKendall Knysch - Head of Media Relations &...Niagen Bioscience (NAGE) Earnings Transcript
Operator: Ladies and gentlemen, thank you for standing by and welcome to Niagen Bioscience Inc. Fourth Quarter 2025 Earnings Conference Call. This afternoon, Niagen Bioscience Inc. issued a news release announcing the company's financial results for 2025. If you have not reviewed this information, it is available within the Investor Relations section of the Niagen Bioscience Inc. website at www.niagenbioscience.com.Niagen Bioscience, Inc. (NAGE): A Bull Case Theory
We came across a bullish thesis on Niagen Bioscience, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on NAGE. Niagen Bioscience, Inc.’s share was trading at $65.99 as of January 29th. NAGE’s trailing and forward P/E were 24.96 and 19.96 respectively according to Yahoo Finance. Niagen Bioscience, Inc. operates as a bioscience company […]
Read more news
Top Health & Nutrition Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Niagen Bioscience
Sign Up For FreeTo access detailed company insights
Niagen Bioscience Inc is a publicly traded bioscience company headquartered in Los Angeles, California, trading on NASDAQ under the ticker symbol NAGE. Founded in 1999 as ChromaDex Corporation, the company officially changed its name to Niagen Bioscience in March 2025, reflecting its focus as the global leader in nicotinamide adenine dinucleotide N... Read More
